Follow
Penn Muluhngwi
Penn Muluhngwi
University of Louiville
Verified email at louisville.edu
Title
Cited by
Cited by
Year
Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells
TT Manavalan, Y Teng, LM Litchfield, P Muluhngwi, N Al-Rayyan, ...
PloS one 8 (4), e62334, 2013
1152013
Roles for miRNAs in endocrine resistance in breast cancer
P Muluhngwi, CM Klinge
Endocrine-related cancer 22 (5), R279, 2015
872015
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer
P Muluhngwi, CM Klinge
Molecular and cellular endocrinology 456, 76-86, 2017
442017
Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells
P Muluhngwi, A Krishna, SL Vittitow, JT Napier, KM Richardson, M Ellis, ...
Cancer letters 388, 230-238, 2017
422017
Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells
BN Radde, MM Ivanova, HX Mai, N Alizadeh-Rad, K Piell, P Van Hoose, ...
Experimental cell research 347 (1), 222-231, 2016
412016
The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells
P Muluhngwi, N Alizadeh-Rad, SL Vittitow, TS Kalbfleisch, CM Klinge
Scientific reports 7 (1), 5205, 2017
382017
Transcriptomic response of breast cancer cells to anacardic acid
DJ Schultz, A Krishna, SL Vittitow, N Alizadeh-Rad, P Muluhngwi, ...
Scientific reports 8 (1), 8063, 2018
372018
Genome-wide miRNA response to anacardic acid in breast cancer cells
DJ Schultz, P Muluhngwi, N Alizadeh-Rad, MA Green, EC Rouchka, ...
PloS one 12 (9), e0184471, 2017
232017
Identification and roles of miR-29b-1-3p and miR29a-3p-regulated and non-regulated lncRNAs in endocrine-sensitive and resistant breast cancer cells
P Muluhngwi, CM Klinge
Cancers 13 (14), 3530, 2021
162021
Cell-free DNA diagnostics: current and emerging applications in oncology
P Muluhngwi, R Valdes Jr, R Fernandez-Botran, E Burton, B Williams, ...
Pharmacogenomics 20 (05), 357-380, 2019
142019
Verification of newly FDA-approved kappa and lambda free light chain assays on a previously untested platform
P Muluhngwi, CN Sharp, N Pozzi, RJ Elin, SA Jortani
Journal of Applied Laboratory Medicine 4 (3), 323-330, 2019
82019
Regulation of miR-29b-1/a transcription and identification of target mRNAs in CHO-K1 cells
P Muluhngwi, K Richardson, J Napier, EC Rouchka, JL Mott, CM Klinge
Molecular and cellular endocrinology 444, 38-47, 2017
82017
A shared diagnostic stewardship approach toward improving autoimmune encephalopathy send-out testing utilization
CN Sharp, A Fletcher, P Muluhngwi, J Snyder, MW Linder, SA Jortani
The Journal of Applied Laboratory Medicine 6 (2), 387-396, 2021
22021
Development of de novo donor‐specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction
R Hod‐Dvorai, R Lee, P Muluhngwi, M Raijmakers, A Shetty, AR Tambur, ...
Transplant Infectious Disease 25 (1), e13993, 2023
12023
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
RH Dvorai, R Lee, P Muluhngwi, M Raijmakers, A Shetty, A Tambur, ...
AMERICAN JOURNAL OF TRANSPLANTATION 21, 454-455, 2021
12021
P610 Donor specific antibodies (DSA) monitoring: The effect of clinical decision support (CDS) intervention on DSA orders
C Scalf, M Greenwood, P Muluhngwi
Human Immunology 84, 166, 2023
2023
P516 A case of false positive Class II antibody reactivity consistent in both the One Lambda and Immucor Luminex single-antigen bead (SAB) assays
P Muluhngwi, A Mollner, H Miller
Human Immunology 84, 140, 2023
2023
Human Leukocyte Antigens and Transplantation
P Muluhngwi, G Tumer
Human Leukocyte Antigens-Updates and Advances, 2023
2023
HLA and Transplantation
P Muluhngwi, G Tumer
IntechOpen, 2023
2023
ASSESSING THE PERFORMANCE OF THREE HLA ANTIBODY ASSAYS IN EVALUATING TRANSPLANT PATIENTS
JD Hoekstra, H Miller, C Scalf, D Maurer, P Muluhngwi
HUMAN IMMUNOLOGY 83, 161-161, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20